Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
One step forward, two steps back for biotech.
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
Tough equity markets as well as competitor developments prompt a narrowed focus.
